SciSparc
VC Fund
Giv'atayim, Israel
SciSparc is a VC fund in Giv'atayim focused on Pharmaceutical and Retail. SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based ontetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries SciSparc invests in
Stages SciSparc invests in
Countries SciSparc invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Corporate Round
- $400k–$700k
Investment Focus
Industry
- Pharmaceutical 3 (60%)
- Retail 1 (20%)
- Cannabis 1 (20%)
- Biopharma 1 (20%)
- Automotive 1 (20%)
Stage
- Post-IPO Debt 1 (20%)
- Corporate Round 1 (20%)
- Post-IPO Equity 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- Israel 3 (60%)
- Canada 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ari Aminetzah
CEO
|
CEO | Total investments: 0 | Find email | |
Adi Zuloff-Shani
CTO
|
CTO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NeuroThera Labs
|
NeuroThera Labs is the clinical-stage biotech focused on cannabinoid therapeutics. | $3.9M / Post-IPO Equity / Aug 18, 2026 | |
| AutoMax Motors is a vehicle importer company. It involved in the parallel importation and selling of various private automobile products. | $1.9M / Post-IPO Debt / Sep 11, 2024 | ||
MitoCareX Bio
|
MitoCareX Bio is a biotechnology company that focuses on the discovery and development of drugs for cancers & other life-threatening diseases. | $400K / Corporate Round / Feb 17, 2023 | |
|
MitoCareX Bio
|
MitoCareX Bio is a biotechnology company that focuses on the discovery and development of drugs for cancers & other life-threatening diseases. | $700K / Corporate Round / Mar 31, 2022 | |
| LaraPharm Ltd. is a group of people joined together by the belief that active components found in the Cannabis plant can provide a real answer to hundreds of types of disease currently not addressed at all, or poorly addressed. | $1.5M / Venture - Series Unknown / Apr 02, 2014 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SciSparc invest in?
SciSparc invests primarily in Pharmaceutical, Retail and Cannabis startups, most often at Post-IPO Debt and Corporate Round stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SciSparc's check size?
SciSparc typically joins rounds of $400k–$700k at Corporate Round. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SciSparc participates in.
How do I contact SciSparc?
Public channels for SciSparc include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SciSparc?
The team at SciSparc includes Ari Aminetzah (CEO) and Adi Zuloff-Shani (CTO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
